)The top 100 stock
market authors
selected for publication
market authors
selected for publication
R.J Steffens » Comments » Single Comment
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most active
Instabloggers.-
1
TraderMark
-
2
Don Dion
-
3
Cliff Wachtel
-
4
Mike Havrilla
-
5
James Quinn
Top Instabloggers » -
1
-
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
-
"The small life science company is a fully owned subsidiary of Generex (GNBT) Biotechnology, and AE37 is currently in a large scale Phase II efficacy study."
Dec 17 18:48 pm
|Rating:
+2
0
All Comments by R.J Steffens »Genentech and Generex: New HER2/neu Research [View article]
Results of the Phase II are not expected for some time, but I just found an early indication that appears in an upcoming peer review from the CVDP. It is part of the final paragraph in this 8 page article:.
Expert Opin Biol Ther. 2009 Jan ;9
CD4(+) T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37).
"Based on early observations of patients enrolled in our Phase II AE37 trial, we are confident that this Ii-Key hybrid peptide will effectively stimulate an HER2/neu-specific immune response and will be an important component as we move forward with our plans to develop a multiepitope vaccine."
lib.bioinfo.pl/auth:Pe...